{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T19:46:17Z","timestamp":1780775177184,"version":"3.54.1"},"reference-count":49,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Telethon-Italy","award":["GGP14096"],"award-info":[{"award-number":["GGP14096"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1016\/j.phrs.2019.01.004","type":"journal-article","created":{"date-parts":[[2019,1,3]],"date-time":"2019-01-03T14:40:22Z","timestamp":1546526422000},"page":"224-235","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"special_numbering":"C","title":["Pharmacogenetics of myotonic hNav1.4 sodium channel variants situated near the fast inactivation gate"],"prefix":"10.1016","volume":"141","author":[{"given":"Alessandro","family":"Farinato","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Concetta","family":"Altamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9140-5350","authenticated-orcid":false,"given":"Paola","family":"Imbrici","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Maggi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0869-2104","authenticated-orcid":false,"given":"Pia","family":"Bernasconi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renato","family":"Mantegazza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Livia","family":"Pasquali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6142-2384","authenticated-orcid":false,"given":"Gabriele","family":"Siciliano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauro","family":"Lo Monaco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Vial","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damien","family":"Sternberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9709-6533","authenticated-orcid":false,"given":"Maria Rosaria","family":"Carrat\u00f9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0162-9698","authenticated-orcid":false,"given":"Diana","family":"Conte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8816-9369","authenticated-orcid":false,"given":"Jean-Fran\u00e7ois","family":"Desaphy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.phrs.2019.01.004_bib0005","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.ncl.2014.04.002","article-title":"Muscle channelopathies","volume":"32","author":"Statland","year":"2014","journal-title":"Neurol. Clin."},{"key":"10.1016\/j.phrs.2019.01.004_bib0010","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1097\/WCO.0000000000000127","article-title":"Muscle channelopathies: recent advances in genetics, pathophysiology and therapy","volume":"27","author":"Suetterlin","year":"2014","journal-title":"Curr. Opin. Neurol."},{"key":"10.1016\/j.phrs.2019.01.004_bib0015","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/164_2017_52","article-title":"Sodium channelopathies of skeletal muscle","volume":"246","author":"Cannon","year":"2018","journal-title":"Handb. Exp. Pharmacol."},{"key":"10.1016\/j.phrs.2019.01.004_bib0020","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1001\/jama.2012.12607","article-title":"Mexiletine for symptoms and signs of myotonia in nondystrophic myotonia: a randomized controlled trial","volume":"308","author":"Statland","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.phrs.2019.01.004_bib0025","first-page":"121","article-title":"Therapeutic approaches to genetic ion channelopathies and perspectives in drug discovery","volume":"7","author":"Imbrici","year":"2017","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.phrs.2019.01.004_bib0030","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1001\/jamaneurol.2015.2338","article-title":"Long-term safety and efficacy of mexiletine for patients with skeletal muscle channelopathies","volume":"72","author":"Suetterlin","year":"2015","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.phrs.2019.01.004_bib0035","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1113\/jphysiol.2001.012541","article-title":"Mexiletine block of disease-associated mutations in S6 segments of the human skeletal muscle Na(+) channel","volume":"537","author":"Takahashi","year":"2001","journal-title":"J. Physiol."},{"key":"10.1016\/j.phrs.2019.01.004_bib0040","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1212\/WNL.57.10.1849","article-title":"Gating of myotonic Na channel mutants defines the response to mexiletine and a potent derivative","volume":"57","author":"Desaphy","year":"2001","journal-title":"Neurology"},{"key":"10.1016\/j.phrs.2019.01.004_bib0045","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1113\/jphysiol.2003.046995","article-title":"Different flecainide sensitivity of hNav1.4 channels and myotonic mutants explained by state-dependent block","volume":"554","author":"Desaphy","year":"2004","journal-title":"J. Physiol."},{"key":"10.1016\/j.phrs.2019.01.004_bib0050","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1007\/s00228-012-1414-3","article-title":"Dramatic improvement of myotonia permanens with flecainide: a two-case report of a possible bench-to-bedside pharmacogenetics strategy","volume":"69","author":"Desaphy","year":"2013","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.phrs.2019.01.004_bib0055","first-page":"125","article-title":"Myotonia permanens with Na1.4-G1306E displays varied phenotypes during course of life","volume":"36","author":"Lehmann-Horn","year":"2017","journal-title":"Acta Myol."},{"key":"10.1016\/j.phrs.2019.01.004_bib0060","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1212\/WNL.0000000000002721","article-title":"Translational approach to address therapy in myotonia permanens due to a new SCN4A mutation","volume":"86","author":"Desaphy","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.phrs.2019.01.004_bib0065","doi-asserted-by":"crossref","first-page":"14279","DOI":"10.18632\/oncotarget.15263","article-title":"Toward precision medicine in myotonic syndromes","volume":"8","author":"De Bellis","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.phrs.2019.01.004_bib0070","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/164_2017_61","article-title":"Structural and Functional analysis of sodium channels viewed from an evolutionary perspective","volume":"246","author":"Gamal El-Din","year":"2018","journal-title":"Handb. Exp. Pharmacol."},{"issue":"September","key":"10.1016\/j.phrs.2019.01.004_bib0075","article-title":"Structure of the human voltage-gated sodium channel Nav1.4 in complex with \u03b21","author":"Pan","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.phrs.2019.01.004_bib0080","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.pain.2009.01.010","article-title":"Involvement of voltage-gated sodium channels blockade in the analgesic effects of orphenadrine","volume":"142","author":"Desaphy","year":"2009","journal-title":"Pain"},{"key":"10.1016\/j.phrs.2019.01.004_bib0085","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3389\/fphar.2012.00017","article-title":"Molecular insights into the local anesthetic receptor within voltage-gated sodium channels using hydroxylated analogs of mexiletine","volume":"3","author":"Desaphy","year":"2012","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.phrs.2019.01.004_bib0090","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1097\/00001756-199510010-00012","article-title":"Paramyotonia congenita without paralysis on exposure to cold: a novel mutation in the SCN4A gene (Val1293Ile)","volume":"6","author":"Koch","year":"1995","journal-title":"NeuroReport"},{"key":"10.1016\/j.phrs.2019.01.004_bib0095","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1002\/ana.20905","article-title":"Cold extends electromyography distinction between ion channel mutations causing myotonia","volume":"60","author":"Fournier","year":"2006","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.phrs.2019.01.004_bib0100","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1212\/WNL.0b013e31828cf8d0","article-title":"Prevalence study of genetically defined skeletal muscle channelopathies in England","volume":"80","author":"Horga","year":"2013","journal-title":"Neurology"},{"key":"10.1016\/j.phrs.2019.01.004_bib0105","doi-asserted-by":"crossref","first-page":"509","DOI":"10.3988\/jcn.2016.12.4.509","article-title":"A large dominant myotonia congenita family with a V1293I mutation in SCN4A","volume":"12","author":"Chung","year":"2016","journal-title":"J. Clin. Neurol."},{"issue":"June","key":"10.1016\/j.phrs.2019.01.004_bib0110","article-title":"Focal and abnormally persistent paralysis associated with congenital paramyotonia","volume":"2014","author":"Magot","year":"2014","journal-title":"BMJ Case Rep."},{"key":"10.1016\/j.phrs.2019.01.004_bib0115","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.pediatrneurol.2017.02.006","article-title":"Spectrum of nondystrophic skeletal muscle channelopathies in children","volume":"70","author":"Al-Ghamdi","year":"2017","journal-title":"Pediatr. Neurol."},{"key":"10.1016\/j.phrs.2019.01.004_bib0120","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s10048-017-0525-5","article-title":"Coexistence of CLCN1 and SCN4A mutations in one family suffering from myotonia","volume":"18","author":"Maggi","year":"2017","journal-title":"Neurogenetics"},{"key":"10.1016\/j.phrs.2019.01.004_bib0125","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1002\/ajmg.a.32141","article-title":"Severe neonatal non-dystrophic myotonia secondary to a novel mutation of the voltage-gated sodium channel (SCN4A) gene","volume":"146A","author":"Gay","year":"2008","journal-title":"Am. J. Med. Genet. A"},{"key":"10.1016\/j.phrs.2019.01.004_bib0130","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2015-3289","article-title":"Flecainide-responsive myotonia permanens with SNEL onset: a new case and literature review","volume":"137","author":"Portaro","year":"2016","journal-title":"Pediatrics"},{"key":"10.1016\/j.phrs.2019.01.004_bib0135","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1212\/01.wnl.0000287069.21162.94","article-title":"What causes paramyotonia in the United Kingdom? Common and new SCN4A mutations revealed","volume":"70","author":"Matthews","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.phrs.2019.01.004_bib0140","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.nmd.2018.03.006","article-title":"Prevalence and mutation spectrum of skeletal muscle channelopathies in the Netherlands","volume":"28","author":"Stunnenberg","year":"2018","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.phrs.2019.01.004_bib0145","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1212\/01.wnl.0000257825.29703.e8","article-title":"Efficacy of propafenone in paramyotonia congenita","volume":"68","author":"Alfonsi","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.phrs.2019.01.004_bib0150","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1002\/mus.10396","article-title":"Paramyotonia congenita due to a de novo mutation: a case report","volume":"28","author":"Fukukome","year":"2003","journal-title":"Muscle Nerve"},{"issue":"February","key":"10.1016\/j.phrs.2019.01.004_bib0155","article-title":"Successful long-term therapy with flecainide in a family with paramyotonia congenita","author":"Terracciano","year":"2018","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.phrs.2019.01.004_bib0160","doi-asserted-by":"crossref","first-page":"856","DOI":"10.2169\/internalmedicine.42.856","article-title":"Thr11313Met mutation in skeletal muscle sodium channels in a Japanese family with paramyotonia Congenita","volume":"42","author":"Kinoshita","year":"2003","journal-title":"Intern. Med."},{"key":"10.1016\/j.phrs.2019.01.004_bib0165","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/S0006-3495(96)79219-6","article-title":"Impaired slow inactivation in mutant sodium channels","volume":"71","author":"Cummins","year":"1996","journal-title":"Biophys. J."},{"key":"10.1016\/j.phrs.2019.01.004_bib0170","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.neuropharm.2016.10.013","article-title":"Increased sodium channel use-dependent inhibition by a new potent analogue of tocainide greatly enhances in vivo antimyotonic activity","volume":"113","author":"De Bellis","year":"2017","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.phrs.2019.01.004_bib0175","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.expneurol.2014.02.023","article-title":"Preclinical evaluation of marketed sodium channel blockers in a rat model of myotonia discloses promising antimyotonic drugs","volume":"255","author":"Desaphy","year":"2014","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.phrs.2019.01.004_bib0180","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/S0006-3495(94)80807-0","article-title":"Slow Na+ channel inactivation must be disrupted to evoke prolonged depolarization-induced paralysis","volume":"66","author":"Ruff","year":"1994","journal-title":"Biophys. J."},{"key":"10.1016\/j.phrs.2019.01.004_bib0185","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1212\/WNL.52.7.1447","article-title":"Defective slow inactivation of sodium channels contributes to familial periodic paralysis","volume":"52","author":"Hayward","year":"1999","journal-title":"Neurology"},{"key":"10.1016\/j.phrs.2019.01.004_bib0190","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1113\/jphysiol.1997.sp021952","article-title":"Human Na+ channel fast and slow inactivation in paramyotonia congenita mutants expressed in Xenopus laevis oocytes","volume":"499","author":"Richmond","year":"1997","journal-title":"J. Physiol."},{"issue":"3","key":"10.1016\/j.phrs.2019.01.004_bib0195","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1111\/j.1469-7793.1998.685bj.x","article-title":"Human sodium channel gating defects caused by missense mutations in S6 segments associated with myotonia: S804F and V1293I","volume":"510","author":"Green","year":"1998","journal-title":"J. Physiol."},{"key":"10.1016\/j.phrs.2019.01.004_bib0200","doi-asserted-by":"crossref","first-page":"3098","DOI":"10.1016\/S0006-3495(96)79504-8","article-title":"Interaction between fast and slow inactivation in Skm1 sodium channels","volume":"71","author":"Featherstone","year":"1996","journal-title":"Biophys. J."},{"key":"10.1016\/j.phrs.2019.01.004_bib0205","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.clinph.2014.06.008","article-title":"Effect of mexiletine on transitory depression of compound motor action potential in recessive myotonia congenita","volume":"126","author":"Lo Monaco","year":"2015","journal-title":"Clin. Neurophysiol."},{"key":"10.1016\/j.phrs.2019.01.004_bib0210","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1085\/jgp.113.1.7","article-title":"The position of the fast-inactivation gate during lidocaine block of voltage-gated Na+ channels","volume":"113","author":"Vedantham","year":"1999","journal-title":"J. Gen. Physiol."},{"issue":"3","key":"10.1016\/j.phrs.2019.01.004_bib0215","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1113\/jphysiol.2003.054973","article-title":"Mexiletine block of wild-type and inactivation-deficient human skeletal muscle hNav1.4 Na+ channels","volume":"554","author":"Wang","year":"2004","journal-title":"J. Physiol."},{"key":"10.1016\/j.phrs.2019.01.004_bib0220","article-title":"Comparison of gating properties and use-dependent block of Nav1.5 and Nav1.7 channels by anti-arrhythmics mexiletine and lidocaine","volume":"10","author":"Wang","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.phrs.2019.01.004_bib0225","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.ejphar.2005.12.021","article-title":"Class Ic antiarrhythmics block human skeletal muscle Na channel during myotonia-like stimulation","volume":"532","author":"Aoike","year":"2006","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.phrs.2019.01.004_bib0230","doi-asserted-by":"crossref","first-page":"385","DOI":"10.3389\/fneur.2018.00385","article-title":"Flecainide-induced Brugada syndrome in a patient with skeletal muscle sodium channelopathy: a case report with critical therapeutical implications and review of the literature","volume":"9","author":"Cavalli","year":"2018","journal-title":"Front. Neurol."},{"key":"10.1016\/j.phrs.2019.01.004_bib0235","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1093\/brain\/awx192","article-title":"The antimyotonic effect of lamotrigine in non-dystrophic myotonias: a double-blind randomized study","volume":"140","author":"Andersen","year":"2017","journal-title":"Brain"},{"key":"10.1016\/j.phrs.2019.01.004_bib0240","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1212\/WNL.0000000000004229","article-title":"Open-label trial of ranolazine for the treatment of myotonia congenita","volume":"89","author":"Arnold","year":"2017","journal-title":"Neurology"},{"key":"10.1016\/j.phrs.2019.01.004_bib0245","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1016\/S0140-6736(18)30021-7","article-title":"Dysfunction of NaV1.4, a skeletal muscle voltage-gated sodium channel, in sudden infant death syndrome: a case-control study","volume":"391","author":"M\u00e4nnikk\u00f6","year":"2018","journal-title":"Lancet"}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661818315172?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661818315172?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,2,23]],"date-time":"2019-02-23T11:57:25Z","timestamp":1550923045000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661818315172"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3]]},"references-count":49,"alternative-id":["S1043661818315172"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2019.01.004","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2019,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacogenetics of myotonic hNav1.4 sodium channel variants situated near the fast inactivation gate","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2019.01.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}